Psoriatic Arthritis Treatment Market Exclusive Report with Detailed Study Analysis By 2025-2032 | Medtronic, Johnson & Johnson (DePuy Synthes)

The Psoriatic Arthritis Treatment market is witnessing considerable evolution driven by advancements in biologic therapies and increasing prevalence of psoriatic arthritis globally. Innovative treatment modalities such as targeted immunomodulators and biosimilars have expanded therapeutic options, ensuring personalized care and better patient outcomes. Adoption of early diagnosis techniques has also enhanced market dynamics, facilitating timely intervention to reduce disease progression. The Global Psoriatic Arthritis Treatment Market size is estimated to be valued at USD 12.19 billion in 2025 and is expected to reach USD 23.47 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.8% from 2025 to 2032.

Get Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/4624

Actionable Insights

- Supply-side indicators show an expansion in biologics production capacity, with a 15% increase in global manufacturing output recorded in 2024, directly impacting market size.
- Pricing analysis highlights competitive adjustments: biosimilar entries in 2025 reduced treatment costs by approximately 12%, driving higher affordability and demand.
- Export volumes of psoriatic arthritis drugs surged by 10% in 2024, predominantly from North America and Europe, signaling increased international market penetration.
- Demand-side trends reveal a 20% rise in patient pool uptake for anti-IL-17 therapies, reflecting shifting preferences toward targeted approaches noted in recent clinical data.
- Micro-indicators, such as enhanced diagnostic tool utilization and rising patient awareness campaigns, have accelerated treatment initiation timelines, positively influencing business growth and market revenue expansion.

Market Segment and Regional Coverage

Comprehensive Segmentation and Classification of the Report:
» By Drug Type: Biologics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDs), Corticosteroids, and Others
» By Route of Administration: Oral, Parenteral, Topical, and Others
» By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others

Regional and Country Analysis:

» North America: U.S. and Canada
» Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
» Europe: Germany, U.K., Spain, France, Italy, Benelux, Denmark, Norway, Sweden, Russia, and Rest of Europe
» Asia Pacific: China, Taiwan, India, Japan, South Korea, Indonesia, Malaysia, Philippines, Singapore, Australia, and Rest of Asia Pacific
» Middle East & Africa: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Israel, South Africa, North Africa, Central Africa, and Rest of MEA

Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/4624

Key Players
The market comprises key players including Medtronic, Johnson & Johnson (DePuy Synthes), Zimmer Biomet, Stryker, Xtant Medical, RTI Surgical, SeaSpine, Arthrex, HansBioMed, Exactech, Wright Medical Group, Bioventus, Integra LifeSciences, AlloSource, Medline Industries, Osiris Therapeutics, Acelity, Orthofix, MTF Biologics, and Cerapedics.
- Johnson & Johnson strategically expanded its Psoriatic Arthritis portfolio in 2024 through the acquisition of a novel biologic platform, resulting in 8% growth in market revenue in Q3 2024.
- Stryker implemented a cost-optimization program focusing on supply chain innovation, improving production efficiency by 12%, enhancing competitive positioning in 2025.
- Medtronic pursued collaborations with specialty clinics to pilot advanced drug delivery systems, which increased its device market penetration by 7% across North America.

Growth Factors
Increasing prevalence of autoimmune diseases, personalized medicine adoption, and rising investment in R&D for novel therapeutics have been pivotal growth drivers. In 2024, clinical trials initiated globally for new IL-23 inhibitors marked a 25% boost compared to the previous year, supporting market expansion. Furthermore, government healthcare funding in key regions aims to enhance access to advanced psoriatic arthritis treatments, promoting sustained business growth.

Market Trends
The increasing integration of digital health platforms for remote monitoring and treatment adherence is a significant trend shaping the Psoriatic Arthritis Treatment market. In 2025, digital therapeutics adoption improved patient compliance rates by 18%, catalyzing better clinical outcomes. Additionally, biosimilars have gained accelerated approval pathways, reducing time-to-market by up to 30%, expanding market opportunities. The trend toward combination therapies has also emerged, leveraging complementary mechanisms to enhance efficacy and market revenue.

Key Takeaways
- Biologics dominate drug type segments, driven by targeted efficacy and patient preference.
- Oral administration remains a preferred route due to convenience and compliance advantages.
- Hospitals constitute the largest end-user segment, offering comprehensive care facilities for psoriatic arthritis patients.
- North America leads with advanced healthcare infrastructure supporting innovative therapies.
- Asia Pacific shows rapid adoption fueled by increasing healthcare access and rise in diagnosed cases.
- Europe maintains steady growth, driven by strong regulatory frameworks and reimbursement policies.

To Purchase This Premium Report, Click Here (Discount of Up to 25%): https://www.coherentmarketinsights.com/insight/buy-now/4624

Frequently Asked Questions

1. Who are the dominant players in the Psoriatic Arthritis Treatment market?
Key market companies include Medtronic, Johnson & Johnson (DePuy Synthes), Zimmer Biomet, and Stryker, among others, leveraging innovation and strategic acquisitions to strengthen their market share.

2. What will be the size of the Psoriatic Arthritis Treatment market in the coming years?
The market size is projected to reach USD 23.47 billion by 2032, growing at a CAGR of 9.8% from 2025 to 2032, driven by rising disease prevalence and therapeutic advancements.

3. Which end-user industry has the largest growth opportunity?
Hospitals represent the largest end-user segment, benefiting from enhanced diagnostic and treatment capabilities facilitating comprehensive patient management.

4. How will market development trends evolve over the next five years?
Trends toward biosimilars adoption, combination therapies, and digital health integration will drive business growth and market revenue, expanding therapeutic options and patient engagement.

5. What is the nature of the competitive landscape and challenges in the Psoriatic Arthritis Treatment market?
Competitive strategies focus on R&D innovation and strategic partnerships, while challenges include regulatory barriers and pricing pressures, requiring adaptive growth strategies.

Author of this Marketing PR:

Ravina Pandya, PR Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.

📞 Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
U.S.: + 12524771362
U.K.: +442039578553
AUS: +61-2-4786-0457
INDIA: +91-848-285-0837

About CMI:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

This release was published on openPR.